facebook button CONTESSA Trio: Tesetaxel Plus Immunotherapy
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

CONTESSA Trio: Tesetaxel Plus Immunotherapy

Sponsor: Odonate Therapeutics, Inc.

Protocol ODO-TE-B202. The CONTESSA Trio trial is a study of oral taxane tesetaxel plus one of nivolumab, pembrolizumab, or atezolizumab in patients with locally advanced or metastatic triple negative breast cancer who have not yet received chemotherapy for their locally advanced or metastatic disease.

Cohort 1: PD-L1 positive TNBC for tesetaxel plus immunotherapy.
Cohort 2: Closed to enrollment.
Cohort 3: Patients 18 to 65 years old with any HER2 negative breast cancer for tesetaxel monotherapy.

For more information please contact the clinical research department: 631-675-5075